, combined hyperlipidemia
) is a commonly occurring form of hypercholesterolemia
levels) characterised by increased LDL
concentrations, often accompanied by decreased HDL
. On lipoprotein electrophoresis
(a test now rarely performed) it shows as a hyperlipoproteinemia type IIB
The elevated triglyceride levels (>5 mmol/l) are generally due to an increase in VLDL (very low density lipoprotein), a class of lipoprotein that is prone to cause atherosclerosis.
There are roughly two forms of this lipid
Both conditions are treated with fibrate
drugs, which act on the peroxisome proliferator-activated receptors
(PPARs), specifically PPARα, to decrease free fatty acid production.
Statin drugs, especially the synthetic statins (atorvastatin and rosuvastatin) can decrease LDL levels by increasing hepatic reuptake of LDL due to increased LDL-receptor expression.